These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Jacobson CA; Sun L; Kim HT; McDonough SM; Reynolds CG; Schowalter M; Koreth J; Cutler CS; Ho VT; Alyea EP; Armand P; Blazar BR; Soiffer RJ; Antin JH; Ritz J; Sarantopoulos S Biol Blood Marrow Transplant; 2014 May; 20(5):668-75. PubMed ID: 24462743 [TBL] [Abstract][Full Text] [Related]
4. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Sarantopoulos S; Stevenson KE; Kim HT; Washel WS; Bhuiya NS; Cutler CS; Alyea EP; Ho VT; Soiffer RJ; Antin JH; Ritz J Blood; 2011 Feb; 117(7):2275-83. PubMed ID: 21097674 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. Kuzmina Z; Gounden V; Curtis L; Avila D; Rnp TT; Baruffaldi J; Cowen EW; Naik HB; Hasni SA; Mays JW; Mitchell S; Baird K; Steinberg SM; Pavletic SZ Am J Hematol; 2015 Feb; 90(2):114-9. PubMed ID: 25363867 [TBL] [Abstract][Full Text] [Related]
6. Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity. Hillhouse EE; Thiant S; Moutuou MM; Lombard-Vadnais F; Parat R; Delisle JS; Ahmad I; Roy DC; Guimond M; Roy J; Lesage S Biol Blood Marrow Transplant; 2019 Jan; 25(1):19-25. PubMed ID: 30244108 [TBL] [Abstract][Full Text] [Related]
7. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Allen JL; Fore MS; Wooten J; Roehrs PA; Bhuiya NS; Hoffert T; Sharf A; Deal AM; Armistead P; Coghill J; Gabriel DA; Irons R; Essenmacher A; Shea TC; Richards K; Cutler C; Ritz J; Serody J; Baldwin AS; Sarantopoulos S Blood; 2012 Sep; 120(12):2529-36. PubMed ID: 22896003 [TBL] [Abstract][Full Text] [Related]
8. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Sarantopoulos S; Stevenson KE; Kim HT; Cutler CS; Bhuiya NS; Schowalter M; Ho VT; Alyea EP; Koreth J; Blazar BR; Soiffer RJ; Antin JH; Ritz J Blood; 2009 Apr; 113(16):3865-74. PubMed ID: 19168788 [TBL] [Abstract][Full Text] [Related]
9. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation. Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723 [TBL] [Abstract][Full Text] [Related]
10. B cells in chronic graft-versus-host disease. McManigle W; Youssef A; Sarantopoulos S Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450 [TBL] [Abstract][Full Text] [Related]
11. The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study. van Dorp S; Resemann H; te Boome L; Pietersma F; van Baarle D; Gmelig-Meyling F; de Weger R; Petersen E; Minnema M; Lokhorst H; Ebeling S; Beijn SJ; Knol EF; van Dijk M; Meijer E; Kuball J Haematologica; 2011 Sep; 96(9):1380-4. PubMed ID: 21546493 [TBL] [Abstract][Full Text] [Related]
12. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation. Kharfan-Dabaja MA; Bazarbachi A Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213 [TBL] [Abstract][Full Text] [Related]
13. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Alousi AM; Uberti J; Ratanatharathorn V Leuk Lymphoma; 2010 Mar; 51(3):376-89. PubMed ID: 20141428 [TBL] [Abstract][Full Text] [Related]
14. CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease. Greinix HT; Kuzmina Z; Weigl R; Körmoczi U; Rottal A; Wolff D; Kralj M; Kalhs P; Mitterbauer M; Rabitsch W; Edinger M; Holler E; Pickl WF Biol Blood Marrow Transplant; 2015 Feb; 21(2):250-8. PubMed ID: 25460358 [TBL] [Abstract][Full Text] [Related]
16. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907 [TBL] [Abstract][Full Text] [Related]
17. Clinical utility of rituximab in chronic graft-versus-host disease. Bates JS; Engemann AM; Hammond JM Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571 [TBL] [Abstract][Full Text] [Related]
18. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Arai S; Sahaf B; Narasimhan B; Chen GL; Jones CD; Lowsky R; Shizuru JA; Johnston LJ; Laport GG; Weng WK; Benjamin JE; Schaenman J; Brown J; Ramirez J; Zehnder JL; Negrin RS; Miklos DB Blood; 2012 Jun; 119(25):6145-54. PubMed ID: 22563089 [TBL] [Abstract][Full Text] [Related]
19. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation. Partanen J; Hyvärinen K; Bickeböller H; Bogunia-Kubik K; Crossland RE; Ivanova M; Perutelli F; Dressel R Front Immunol; 2020; 11():575492. PubMed ID: 33193367 [TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Kanda J; Lopez RD; Rizzieri DA Int J Hematol; 2011 May; 93(5):586-593. PubMed ID: 21369856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]